α-Glucosidase inhibitors are widely used in the treatment of patients with T2DM, which delay the absorption of carbohydrates from the small intestine and result in lowered postprandial blood glucose and insulin levels (99). This evidence concerns the gene INS and type 2 diabetes mellitus.